Atea Pharmaceuticals (AVIR) financial statements
Net income was -$158M.
The diluted share count rose 712% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Atea Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $49M | $351M | — | — | — | — |
| Research and development | $7M | $10M | $38M | $167M | $82M | $114M | $144M | $148M |
| Selling, general and admin | $3M | $4M | $22M | $46M | $49M | $50M | $49M | $33M |
| Operating income | -$9M | -$15M | -$11M | $138M | -$131M | -$164M | -$193M | -$181M |
| Pre-tax income | — | -$14M | -$11M | $139M | -$119M | -$135M | -$167M | -$165M |
| Income tax | — | — | — | $17M | -$4M | $1M | $925,000 | -$6M |
| Net income | -$9M | -$14M | -$11M | $121M | -$116M | -$136M | -$168M | -$158M |
| EPS (diluted) | -$0.90 | -$1.39 | -$0.51 | $1.37 | -$1.39 | -$1.63 | -$2.00 | -$1.94 |
| Diluted shares | 10M | 10M | 22M | 88M | 83M | 83M | 84M | 81M |
| Operating margin | — | — | -22.7% | 39.4% | — | — | — | — |
| Net margin | — | — | -22.5% | 34.5% | — | — | — | — |
Balance sheet
Fiscal years, from Atea Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $34M | $22M | $850M | $764M | $647M | $578M | $455M | $302M |
| Total current assets | — | $22M | $863M | $772M | $661M | $590M | $462M | $311M |
| Property, plant and equipment | — | $41,000 | $48,000 | $23,000 | $2M | $1M | $873,000 | $457,000 |
| Total assets | — | $22M | $864M | $773M | $667M | $595M | $465M | $315M |
| Total current liabilities | — | $2M | $316M | $57M | $18M | $32M | $19M | $40M |
| Total liabilities | — | $3M | $316M | $63M | $26M | $40M | $26M | $40M |
| Shareholders' equity | -$36M | -$50M | $548M | $710M | $641M | $555M | $439M | $275M |
| Net debt | -$34M | -$22M | -$850M | -$764M | -$188M | -$144M | -$65M | -$96M |
Cash flow
Fiscal years, from Atea Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8M | -$13M | $297M | -$87M | -$121M | -$85M | -$135M | -$132M |
| Capital spending | $12,000 | $2,000 | $26,000 | $4,000 | $2M | — | — | — |
| Free cash flow | -$8M | -$13M | $297M | -$87M | -$123M | — | — | — |
| Stock-based compensation | $414,000 | $624,000 | $7M | $40M | $47M | $49M | $52M | $21M |
| Share buybacks (net) | — | — | — | — | — | — | $0 | -$26M |
| Free cash flow margin | — | — | 610.1% | -24.8% | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AVIR.
Open AVIR in InvestinglyFrom Atea Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.